8 recruiting, 1 not yet recruiting. 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 8, Not yet recruiting 1 |
Follow Inflammatory Myopathy: new trials by email Literature Review of Inflammatory Myopathy trials Research Report on Inflammatory Myopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases TI-0032-III injection - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS) | Phase 1 | Recruiting | Therorna | 12 | 2026-01-22 | 2026-10-19 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-13 | 2026-10-21 |
| A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-08-04 | 2026-10-21 |
| A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 12 | 2025-05-19 | 2026-10-21 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy | Phase 1 | Recruiting | iCell Gene Therapeutics | 10 | 2025-03-20 | 2026-07-20 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases UCAR T-cell - Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2025-02-11 | 2025-09-29 |
Myositis (9) · Lupus Erythematosus, Systemic (8) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7) · Scleroderma, Systemic (6) · Antiphospholipid Syndrome (5) · Lupus Nephritis (3) · Sjogren's Syndrome (3) · Autoimmune Diseases (2) · Immunoglobulin G4-Related Disease (2) · Recurrence (2) · Anemia, Hemolytic, Autoimmune (1) · Antisynthetase syndrome (1) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Myasthenia Gravis (1)
Connective Tissue Diseases (9) · Muscular Diseases (9) · Musculoskeletal Diseases (9) · Nervous System Diseases (9) · Neuromuscular Diseases (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Immune System Diseases (8) · Cardiovascular Diseases (7) · Skin Diseases, Vascular (7) · Systemic Vasculitis (7) · Vascular Diseases (7) · Vasculitis (7) · Autoimmune Diseases (6) · Arthritis (4)
China Immunotech (Beijing) Biotechnology Co., Ltd. (5) · Changzhou No.2 People's Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Therorna (1) · iCell Gene Therapeutics (1)
China (9)